Short-duration therapy with daclatasvir/asunaprevir/beclabuvir fixed-dose combination plus sofosbuvir in patients with chronic hepatitis C genotype 1 (FOURward Study)

被引：0
|
作者：
Sulkowski, Mark S. [1 ]
Flamm, Steven L. [2 ]
Kayali, Zeid [3 ]
Lawitz, Eric [4 ]
Kwo, Paul Y. [5 ]
McPhee, Fiona [6 ]
Torbeyns, Anne [7 ]
Hughes, Eric A. [8 ]
Swenson, Eugene S. [6 ]
Yin, Philip [6 ]
Linaberry, Misti [8 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] Inland Empire Liver Fdn, Rialto, CA USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA
[5] Indiana Univ, Indianapolis, IN 46204 USA
[6] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[7] Bristol Myers Squibb, Braine Lalleud, Belgium
[8] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
702
引用
收藏
页码：556A / 556A
页数：1
相关论文
共 50 条
  • [21] EFFECT OF BASELINE FACTORS ON RESPONSE TO THE FIXED-DOSE COMBINATION OF DACLATASVIR (DCV), ASUNAPREVIR (ASV) AND BECLABUVIR (BCV), WITH OR WITHOUT RIBAVIRIN (RBV), IN PATIENTS WITH HCV GENOTYPE 1 INFECTION AND CIRRHOSIS
    Hezode, C.
    Herring, R., Jr.
    Pockros, P. J.
    Sheikh, A.
    Vierling, J.
    Lee, S.
    Thompson, A.
    Bhore, R.
    Hughes, E. A.
    Swenson, E. S.
    Yin, P. D.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S676 - S676
  • [22] Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and Beclabuvir (BCV), With or Without Ribavirin (RBV), in Patients With HCV Genotype 1 Infection and Cirrhosis
    Hezode, Christophe
    Herring, Robert W.
    Pockros, Paul J.
    Sheikh, Aasim M.
    Vierling, John M.
    Lee, Samuel
    Thompson, Alex J.
    Bhore, Rafia
    Hughes, Eric A.
    Swenson, Eugene S.
    Yin, Philip D.
    GASTROENTEROLOGY, 2015, 148 (04) : S1083 - S1084
  • [23] Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b
    Yuchen Liu
    Zhenhua Wang
    Ruoyan Gai Tobe
    Houwen Lin
    Bin Wu
    Clinical Drug Investigation, 2018, 38 : 427 - 437
  • [24] Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
    Oh, Jae Young
    Kim, Byung Seok
    Lee, Chang Hyeong
    Song, Jeong Eun
    Lee, Heon Ju
    Park, Jung Gil
    Hwang, Jae Seok
    Chung, Woo Jin
    Jang, Byoung Kuk
    Kweon, Young Oh
    Tak, Won Young
    Park, Soo Young
    Jang, Se Young
    Suh, Jeong Ill
    Kwak, Sang Gyu
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (04): : 794 - 801
  • [25] Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b
    Liu, Yuchen
    Wang, Zhenhua
    Tobe, Ruoyan Gai
    Lin, Houwen
    Wu, Bin
    CLINICAL DRUG INVESTIGATION, 2018, 38 (05) : 427 - 437
  • [26] Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection
    Huang, Chung-Feng
    Yu, Ming-Lung
    KIDNEY INTERNATIONAL, 2020, 97 (03) : 615 - 615
  • [27] DACLATASVIR plus ASUNAPREVIR VERSUS SOFOSBUVIR/LEDIPASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN JAPANESE PATIENTS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Swallow, E.
    Kelley, C.
    Ristovska, L.
    Signorovitch, J. E.
    Kalsekar, A.
    Wygant, G.
    McPhee, F.
    VALUE IN HEALTH, 2015, 18 (07) : A576 - A576
  • [28] Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
    Suda, Goki
    Kudo, Mineo
    Nagasaka, Atsushi
    Furuya, Ken
    Yamamoto, Yoshiya
    Kobayashi, Tomoe
    Shinada, Keisuke
    Tateyama, Miki
    Konno, Jun
    Tsukuda, Yoko
    Yamasaki, Kazushi
    Kimura, Megumi
    Umemura, Machiko
    Izumi, Takaaki
    Tsunematsu, Seiji
    Sato, Fumiyuki
    Terashita, Katsumi
    Nakai, Masato
    Horimoto, Hiromasa
    Sho, Takuya
    Natsuizaka, Mitsuteru
    Morikawa, Kenichi
    Ogawa, Koji
    Sakamoto, Naoya
    JOURNAL OF GASTROENTEROLOGY, 2016, 51 (07) : 733 - 740
  • [29] Safety and efficacy of daclatasvir plus asunaprevir combination therapy in hemodialysis patients infected with hepatitis C virus genotype 1b
    Miyase, Shiho
    Mizobe, Keiko
    Tsukano, Natsumi
    Iwashita, Hirohumi
    Fujiyama, Shigetoshi
    HEPATOLOGY, 2016, 64 : 479A - 479A
  • [30] Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan
    Koichi Takaguchi
    Hidenori Toyoda
    Akemi Tsutsui
    Yoshiyuki Suzuki
    Makoto Nakamuta
    Michio Imamura
    Tomonori Senoh
    Takuya Nagano
    Toshifumi Tada
    Yoshihiko Tachi
    Atsushi Hiraoka
    Kojiro Michitaka
    Hiroshi Shibata
    Kouji Joko
    Hironao Okubo
    Kunihiko Tsuji
    Shintaro Takaki
    Tsunamasa Watanabe
    Chikara Ogawa
    Kazuaki Chayama
    Takashi Kumada
    Masatoshi Kudo
    Hiromitsu Kumada
    Journal of Gastroenterology, 2019, 54 : 742 - 751
12345